Premium
Association of HMGB 1 and HMGB 2 genetic polymorphisms with lung cancer chemotherapy response
Author(s) -
Wang Ying,
Li XiangPing,
Yin JiYe,
Zhang Yu,
He Hui,
Qian ChenYue,
Chen Juan,
Zheng Yi,
Smieszkol Kamila,
Fu YiLan,
Chen ZiYu,
Zhou HongHao,
Liu ZhaoQian
Publication year - 2014
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12232
Subject(s) - single nucleotide polymorphism , chemotherapy , hmgb1 , lung cancer , genotype , medicine , oncology , biology , gene , genetics , receptor
Summary The aim of the present study was to investigate the association of genetic polymorphisms in high mobility group box 1 and 2 ( HMGB 1 and HMGB 2 , respectively) with platinum‐based chemotherapy responses in C hinese lung cancer patients. In total, 338 Chinese lung cancer patients (154 responders and 184 non‐responders) were recruited to the study. All patients received at least two cycles of first‐line platinum‐based chemotherapy. Three tagging single nucleotide polymorphisms ( SNP s) of HMGB 1 and two tagging SNP s of HMGB 2 were detected in patients. We found that rs1412125 and rs2249825 of HMGB 1 were significantly associated with the platinum‐based chemotherapy response in both recessive and genotypic models. In addition, rs1412125 showed significant association with platinum‐based chemotherapy response for the subgroup of patients aged >55 years in additive, recessive and genotypic models. No significant associations were detected between other SNP s and the platinum‐based chemotherapy response. The HMGB 1 SNP s (rs1412125 and rs2249825) were associated with platinum‐based chemotherapy responses in Chinese lung cancer patients. In conclusion, HMGB 1 SNP s may serve as potential biomarkers for predicting the efficacy of platinum‐based chemotherapy.